Evidence map›Paper›PMID 36320932›Full record

ArticleGenetics research2022

Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz.

Parham Mardi, Bahareh Tavakoli-Far, Samira Sheibani Nia, Roshanak Jazayeri, Massoud Houshmand

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genetics research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Parham MardiStudent Research Committee, Alborz University of Medical Sciences, Karaj, Iran.ORCID 0000-0002-9228-4615
Bahareh Tavakoli-FarDietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Samira Sheibani NiaDepartment of Medical Genetics, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Roshanak JazayeriNon-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.ORCID 0000-0002-3230-4610
Massoud HoushmandDepartment of Medical Genetics, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.ORCID 0000-0002-2198-223X
Jahrom University of Medical Sciences · IRNational Institute of Genetic Engineering and Biotechnology · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Efavirenz is an antihuman immunodeficiency virus (HIV) drug metabolized by cytochrome P450 2B6 (CYP2B6) enzyme. Cytochrome P450 2B6 is an enzyme that in humans is encoded by the CYP2B6 gene. Polymorphisms of this gene play a crucial role in the metabolism of drugs such as Efavirenz. This study aims to evaluate the frequency of three clinically significant CYP2B6 polymorphisms (CYP2B6 Methods: One hundred forty-seven participants from three main Iranian ethnicities were included in this study. After DNA extraction, CYP2B6 Results: The frequency of the mutated allele in the Iranian population for CYP2B6 Conclusion: Kurds are at higher risk of adverse drug reactions (ADRs) and insufficient anti-HIV response compared to other Iranians.

Indexed as

HIV InfectionsAlkynesAllelesBenzoxazinesCyclopropanesCytochrome P-450 CYP2B6Gene FrequencyHumansIranPolymorphism, Single NucleotideAlkynesBenzoxazinesCyclopropanesCYP2B6 protein, humanCytochrome P-450 CYP2B6efavirenz

Identifiers

PMID36320932
PMCPMC9605844
OpenAlexW4306809822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.